Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

Fintel reports that on February 12, 2025, Morgan Stanley downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Company initiating process to leverage balance sheet strength to maximize shareholder value ...

Third Harmonic Bio, Inc. (THRD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates ...

Morgan Stanley downgraded Third Harmonic Bio (THRD) to Equal Weight from Overweight with a price target of $5, down from $20, after the company ...

Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform.Maximize Your Portfolio with Data Driven Insights:Leverage ...

Third Harmonic Bio will halt non-THB335 research and cut 50% of its workforce while reviewing strategic options. Get real-time earnings alerts before the market moves and access expert analysis ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...